Overview

IMPACT Study (Improving Measurements of Persistence on "ACtonel" Treatment)

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the impact of physician's reinforcement using bone marker data on the subject's compliance (at least 50% drug taken) and persistence on treatment after one year in postmenopausal osteoporotic women.
Phase:
Phase 3
Details
Lead Sponsor:
Sanofi
Collaborator:
Procter and Gamble
Treatments:
Risedronate Sodium
Risedronic Acid